A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366

NCT03378648 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma
Chronic Obstructive Pulmonary Disease

Interventions

DRUG: CHF6366
DRUG: Placebo CHF6366
DRUG: umeclidinium bromide and vilanterol trifenatate

Sponsor

Chiesi Farmaceutici S.p.A.